DailyIQ
Last updated 1 hour ago

PODD·Insulet Corporation

$.
-. (-.%)
High
$155.73
Open
$154.99
Market Cap
10.73B
52W High
$354.88
Low
$153.15
P. Close
$154.87
P/E
35.41
52W Low
$145.59
Fwd P/E
19.22
Mean Target
-
Technical Score (1D)
23
SELL
News Sentiment
58
BULLISH
Analysts maintain a strongly optimistic outlook on Insulet's long-term growth trajectory, despite recent underperformance relative to the broader market. This sentiment suggests underlying confidence in the company's strategic positioning and market opportunities. The article identifies PODD as a stock potentially poised for a comeback, suggesting its recent price decline may present a buying opportunity. Investors are encouraged to evaluate underlying fundamentals to distinguish temporary setbacks from structural issues. Focus remains on future growth prospects and potential catalysts. Watch for further analyst commentary for insights into specific growth drivers.
Earnings Summary
Insulet Corporation is a medical device company focused on developing and manufacturing innovative insulin delivery systems for individuals with insulin-dependent diabetes, primarily through its Omnipod platform. Operating within the Healthcare sector's Medical Devices industry, the company's core products include the automated Omnipod 5 system and the Omnipod DASH system, alongside manufacturing pods for Amgen's Neulasta Onpro kit. In the most recent reported quarters, Insulet demonstrated a mixed performance against analyst expectations. For Q4 2025, the company reported EPS of $1.55, exceeding the estimate of $1.17827, and revenue of $783.8 million, surpassing the estimate of $714.3266 million. However, in Q1 2026, while EPS of $1.42 beat the estimate of $1.1907, revenue of $761.7 million fell short of the $730.10084 million estimate. This pattern suggests a recent trend of EPS beats alongside occasional revenue misses. Historically, Insulet has shown a trajectory of growth, with notable beats in EPS in Q4 2025 and Q1 2026, although revenue performance has been less consistent, missing estimates in Q1 2026. Recent news highlights analyst optimism regarding Insulet's long-term growth, with Benchmark initiating coverage with a "Buy" rating and a $250 price target, citing strategic international expansion in the Middle East and North Africa. Despite strong Q1 revenue growth driven by Omnipod 5 adoption, concerns about the growth trajectory have led some analysts, like Goldman Sachs, to reduce price targets. Investors will be watching for continued adoption of the Omnipod 5, particularly in the type 2 diabetes segment, and how the company navigates seasonality and insurance deductible resets in its upcoming quarterly reports, as well as the impact of its international expansion efforts on overall growth and profitability.

EPS

EstBeatMiss
$0.67$0.92$1.17$1.42$1.66Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.45 - -
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%
Q1'25$0.79$1.02+29.7%

Revenue

EstBeatMiss
$534M$610M$685M$760M$836MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$801M - -
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -
Q1'25 - $569M -

Market Data

PODD Stock Snapshot

PODD is currently trading at $153.58, giving Insulet Corporation a market cap of 10.73B and a P/E ratio of 35.4. Today's range spans $153.15–$155.73, with shares opening at $154.99 and moving down $1.29 (0.8%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 58/100.

Over the past year PODD has traded between $145.59 and $354.88 - the current price is +5.5% off the 52-week low and -56.7% from the high.

Earnings estimate risk is at the forefront for Insulet Corporation (PODD) - a large-cap Healthcare name (10.73B market cap) showing a SELL (23/100) alongside neutral sentiment (58/100) often flags a period where consensus estimates are still catching down to what the market is already pricing in. Price: $153.58 (near 52-week lows in $145.59–$354.88). (P/E: 35.4) Active managers who track the technical-fundamental gap tend to position ahead of the revision, not after it.

The current SELL phase for PODD (23/100) at $153.58 (near 52-week lows) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 58/100 (neutral) confirms that news flow is not providing a counternarrative. At 10.73B in Healthcare capitalization, PODD has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $145.59–$354.88 range.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…